GE Healthcare Submits Application to European Medicines Agency for Its Own Manufacturing of Optison™ 0.19 mg/ml Dispersion for Injection (Human Albumin Microspheres Containing Perflutren)

Published: Mar 29, 2013

CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE Healthcare today announced that it has submitted an application to amend its European Marketing Authorisation that will allow the company to manufacture Optison™ 0.19 mg/ml dispersion for injection within its own facility. Upon approval, GE Healthcare will provide supply of Optison to the EU market from its manufacturing facility in Oslo, Norway.

Back to news